ASIT biotech Announces the Approval by the Regulatory Authorities of a Follow-up Study of the Phase I/IIa Clinical Trial with its hdm-ASIT+™ Product Candidate for House Dust Mite Rhinitis

A subset of patients treated during the Phase I/IIa clinical trial with its hdm-ASIT+™ product candidate for house dust mite rhinitis will undergo a complementary medical visit to assess potential long-term effect of hdm-ASIT+™

BRUSSELS--(BUSINESS WIRE)-- Regulatory News:

ASIT biotech (Euronext: ASIT - BE0974289218) (Paris:ASIT) (BSE:ASIT), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announces it has received the approval of the regulatory authorities and ethical committee to start a follow-up study with the patients enrolled during the Phase I/IIa clinical trial of its product candidate for house dust mite rhinitis (see press release from 4 April 2017).

The study is carried out at the Carl Gustav Carus University Hospital in Dresden, Germany. The conjunctival provocation test (CPT)¹ showed a slight numerical difference in favor of the treated group compared to the placebo group in the original study. The objective of this follow-up study is to evaluate whether longer natural exposure to house dust mites may have an impact on immunological and reactivity parameters, and assess a potential long-term effect of hdm-ASIT+™.

A subset of the 36 initially randomized patients (27 treated with hdm-ASIT+™ and 9 with placebo) will undergo a complementary medical visit in order to assess their reactivity score to a CPT and their titles of house dust mite allergen specific antibodies (IgG, IgG4, IgE and blocking antibodies).

Thierry Legon, CEO of ASIT biotech, says: “The immunogenicity parameters and CPT score that were tested as a secondary endpoint one week after the end of the treatment with hdm-ASIT+™ were improved between the treated group and the placebo. It is clinically and scientifically sound to test a potential long-term effect of our product against house dust mite-induced rhinoconjunctivitis. An increase of the IgG4 and the blocking antibodies associated to a reduction of the CPT score in treated patients would show that a long term natural challenge is needed to allow the treatment clinical efficacy. In parallel to this follow-up study, we are actively working on the design of an optimized version of hdm-ASIT+™ based on our improved understanding of the mechanism of action of our lead product gp-ASIT+™ following the results of the Phase III study in grass pollen rhinitis.”

***

About hdm-ASIT+™
hdm-ASIT+™ product candidate for the treatment of house dust mite allergy consists of a mixture of natural allergen fragments obtained from a purified specific proteinic extract from house dust mite (dermatophagoides pteronyssinus). In contrast to the synthetized peptides, the natural peptides (70% of the fragments ranging from 1,000The administration schedule of the treatment should be of short duration compared with currently commercialised treatments. This should constitute a major competitive advantage to improve the acceptance and the compliance of the patients. In addition, the administration schedule includes successive injections with half of the visit dose in both arms, an innovative solution that enables the delivery of the total dose necessary for the therapeutic effect in a faster and safer way. Finally, the product candidate is formulated without adjuvant, which increases the long-term safety of the product by decreasing the local and general reactogenicity as well as the frequency of the adverse events, which represents a further advantage in markets less permissive to adjuvanted formulations (e.g. US).

About ASIT biotech
ASIT biotech is a Belgian clinical stage biopharmaceutical company focused on the development and future commercialisation of a range of breakthrough immunotherapy products for the treatment of allergies. Thanks to its innovative ASIT+™ technology platform, ASIT biotech is currently the only developer of AIT product candidates consisting of a unique mixture of highly purified natural allergen fragments in an optimal size selection. This innovation results in a short treatment, expected to improve patient compliance and real-life effectiveness. ASIT biotech’s product pipeline entails two novel ASIT+™ product candidates targeting respiratory allergy with the highest prevalence (i.e. grass pollen: gp-ASIT+™ and house dust mite: hdm-ASIT+™), that could significantly expand the current immunotherapy market. The Company believes that its innovative ASIT+™ platform is flexible and would be applicable across a range of allergies.

ASIT biotech has a headcount of 22 staff members, at its headquarters in Brussels and a laboratory in Liège, Belgium.

Further information can be found at: www.asitbiotech.com.

Forward Looking Statements

All statements in this announcement that do not relate to historical facts and events are “forward-looking statements”. In some cases, these forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes,” “estimates,” “anticipates,” “expects,” “intends,” “may,” “will,” “plans,” “continue,” “ongoing,” “potential,” “predict,” “project,” “target,” “seek” or “should” or, in each case, their negative or other variations or comparable terminology or by discussions of strategies, plans, objectives, targets, goals, future events or intentions. Forward-looking statements include statements regarding the Company’s intentions, beliefs or current expectations. By their nature, forward-looking statements involve known and unknown risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance. Given these risks and uncertainties, you should not rely on forward-looking statements as a prediction of actual results. Any forward-looking statements are made only as of the date of this announcement and, without prejudice to the Company’s obligations under applicable law in relation to disclosure and ongoing information, the Company does not intend, and does not assume any obligation, to update the forward-looking statements set forth in this announcement.

Important Legal Notice

This announcement does not constitute, or form part of, an offer or invitation to sell or issue, or any solicitation of an offer to purchase or subscribe for shares of ASIT biotech SA (the “Company” and the “Shares”). Any purchase of, subscription for or application for, Shares to be issued in connection with the intended offering should only be made on the basis of information contained in the prospectus and any supplements thereto, as the case may be. This announcement does not constitute a prospectus and the information contained herein is for information purposes only and does not purport to be full or complete. Investors should not subscribe for any Shares except on the basis of the information contained in the prospectus that the Company expects to publish after its approval by the Belgian Financial Services and Markets Authority, and which can then be obtained at the Company’s registered office and on www.asitbiotech.com.

This announcement is not for distribution, directly or indirectly, in or into the United States or to any U.S. person within the meaning of the U.S. Securities Act of 1933, as amended (the “Securities Act”). The Shares have not been and will not be registered under the Securities Act and may not be offered or sold in the United States, except pursuant to an exemption from the registration requirements of the Securities Act. The Company has not registered, and does not intend to register, any portion of the intended offering of Shares in the United States, and does not intend to conduct a public offering of Shares in the United States.

This announcement and the information contained herein are not for publication, distribution or release in or into the United States, Australia, Canada, Japan or any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

The Company is responsible for the information contained in this press release.

¹ A test enabling both the diagnosis of a patient’s allergy and the determination of their level of hypersensitivity at various times during the desensitization process.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170816005698/en/

Company

Thierry Legon, CEO

ASIT biotech

Tel. +32 2 264 03 90

[email protected]

or

Media and Investor Relations - France

NewCap

Dusan Oresansky / Pierre Laurent

Tel.: +33 1 44 71 94 92

[email protected]

or

Media Relations - Belgium

Laure-Eve Monfort, Tel.: +32 2 290 90 93

[email protected]

Source: ASIT biotech